ArticleActa crystallographica. Section E, Structure reports online2011
1,3-Bis[2-(2-oxo-1,3-oxazolidin-3-yl)eth-yl]-1H-benzimidazol-2(3H)-one.
Article in Acta crystallographica. Section E, Structure reports online, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Crystal structure, Hirshfeld surface analysis and DFT studies of 1-benzyl-3-[(1-benzyl-1Acta crystallographica. Section E, Crystallographic communications · 2020Article
- Crystal structure, Hirshfeld surface analysis and inter-action energy and DFT studies of 1-methyl-3-(prop-2-yn-1-yl)-2,3-di-hydro-1Acta crystallographica. Section E, Crystallographic communications · 2019Article
- Crystal structure and Hirshfeld surface analysis of 1-{[2-oxo-3-(prop-1-en-2-yl)-2,3-di-hydro-1Acta crystallographica. Section E, Crystallographic communications · 2018Article
- Crystal structure and Hirshfeld surface analysis of 1-benzyl-3-(prop-2-yn-1-yl)-2,3-di-hydro-1Acta crystallographica. Section E, Crystallographic communications · 2018Article
- Crystal structure of 5-chloro-1,3-bis-[2-(2-oxo-1,3-oxazolidin-3-yl)eth-yl]-1H-benz-imidazol-2(3H)-one.Acta crystallographica. Section E, Crystallographic communications · 2015Article
- 5-Nitro-1,3-bis-(prop-2-yn-yl)-1H-1,3-benzimidazol-2(3H)-one.Acta crystallographica. Section E, Structure reports online · 2013Article
- 1-(Prop-2-yn-yl)-1H-benzimidazol-2(3H)-one.Acta crystallographica. Section E, Structure reports online · 2013Article
- 1,3-Dibenzyl-1H-benzimidazol-2(3H)-one.Acta crystallographica. Section E, Structure reports online · 2011Article
- 1-Decyl-6-nitro-1H-benzimidazol-2(3H)-one.Acta crystallographica. Section E, Structure reports online · 2011Article
- 1-Benzyl-1H-benzimidazol-2(3H)-one.Acta crystallographica. Section E, Structure reports online · 2011Article
- 1,3-Bis(prop-2-yn-yl)-1H-1,3-benzimid-azol-2(3H)-one.Acta crystallographica. Section E, Structure reports online · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The mol-ecular structure of the title compound, C(17)H(20)N(4)O(5), contains a central fused-ring system, comprised of six- and five-membered rings. This unit is linked by C(2) chains to two 2-oxo-1,3-oxazolidine five-membered rings. The central fused-ring system is essentially planar, with a maximum deviation of 0.008 (1) Å from the mean plane. Both oxazolidine five-membered rings are also nearly planar, with maximum deviations of 0.090 (1) and 0.141 (1) Å.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.